Inventera KRX:0007J0KOSDAQ
인벤테라 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked10since Sep 11
In Q2 2026, Inventera reported revenue of ₩0m and an operating loss of ₩2.5bn. Inventera (인벤테라) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 21 with 4 articles. The most common catalyst was clinical & approvals (2). It was most often mentioned alongside Bluemtec, Vaxcell-Bio Therapeutics and Cellid.
Filing signals Clinical trial filing Screener
Inventera quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩0m | – | −₩2.5bn | −₩2.3bn |
| Q2 2025 | ₩0m | – | −₩1.6bn | −₩1.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Inventera top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6